Detalhe da pesquisa
1.
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
J Hepatol
; 64(1): 19-28, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26321288